122 results
8-K
EX-99.1
ENVB
Enveric Biosciences Inc
27 Dec 23
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
8:05am
. Complete analysis and final reporting are expected by the end of December 2023.
In vitro assessment of cardiotoxicity potential, involving assays
424B4
ENVB
Enveric Biosciences Inc
6 Dec 23
Prospectus supplement with pricing info
4:00pm
an auditor attestation of management’s assessment of internal control over financial reporting, which is generally required for SEC reporting companies under
8-K
EX-10.3
soytdn codwruj1
26 Jul 22
Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules
5:15pm
8-K
EX-99.1
wz8ahkp2imjl6lnf
13 Jul 22
Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio
10:34am
8-K
EX-10.3
drhvtub70sb5h12me
11 May 22
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
1:46pm
424B3
x7jju
6 Aug 21
Prospectus supplement
4:31pm
8-K/A
h7bh3 tb5
29 Jun 21
Changes in Registrant's Certifying Accountant
4:05pm